Is Change in Hemoglobin Level a Predictive Biomarker of Tyrosine Kinase Efficacy in Metastatic Renal Cell Carcinoma? A Turkish Oncology Group Study.
BACKGROUND
There are insufficient predictive markers for renal cell carcinoma (RCC).


METHODS
A total of 308 metastatic RCC patients were analyzed retrospectively.


RESULTS
The increased hemoglobin (Hb) group had significantly higher progression-free survival and overall survival (OS) compared with the decreased Hb group at 11.5 versus 6.35 months (p < .001) and 21.0 versus 11.36 months (p < .001) respectively. The 1- and 3-year OS rates were higher in the Hb increased group, i.e., 84% versus 64% and 52% versus 35% respectively.


CONCLUSIONS
The present study showed that increased Hb levels after tyrosine kinase inhibitor therapy could be a predictive marker of RCC.
a Department of Internal Medicine and Medical Oncology , Sakarya University School of Medicine , Sakarya , Turkey.
Cemil
C
Bilir
b Acıbadem Atakent Hospital , Istanbul , Turkey.
İbrahim
İ
Yıldız
c Department of Medical Oncology , Medipol University School of Medicine , Istanbul , Turkey.
Ahmet
A
Bilici
d Department of Medical Oncology , Erciyes University School of Medicine , Kayseri , Turkey.
Mahmut
M
Ucar
d Department of Medical Oncology , Erciyes University School of Medicine , Kayseri , Turkey.
Veli
V
Berk
e Department of Medical Oncology , Izmir Katip Çelebi University School of Medicine , Izmir , Turkey.
Yaşar
Y
Yıldız
f Department of Medical Oncology , Ankara Numune Teaching and Education Hospital , Ankara , Turkey.
Ozan
O
Yazıcı
g Department of Medical Oncology , Dışkapı Teaching and Education Hospital , Ankara , Turkey.
Gökşen İnanç
Gİ
İmamoğlu
h Department of Medical Oncology , Gulhane School of Medicine , Ankara , Turkey.
Nuri
N
Karadurmuş
i Department of Medical Oncology , Haseki Teaching and Education Hospital , Istanbul , Turkey.
Kezban Nur
KN
Pilancı
j Department of Medical Oncology , Bülent Ecevit University School of Medicine , Zonguldak , Turkey.
Erkan
E
Arpacı
k Department of Medical Oncology , Mugla Sıtkı Koçman University School of Medicine , Mugla , Turkey.
Özgür
Ö
Tanrıverdi
l Department of Medical Oncology , Ankara University School of Medicine , Ankara , Turkey.
Ebru
E
Karcı
m Acıbadem Kocaeli Hospital , Kocaeli , Turkey.
Süleyman
S
Temiz
n Department of Medical Oncology , Kahramanmaras Necip Fazil City Hospital , Kahramanmaras , Turkey.
Erdinc
E
Nayır
o Department of Medical Oncology , Adnan Menderes University Faculty of Medicine , Aydin , Turkey.
Esin
E
Oktay
p Department of Medical Oncology , Eskisehir Osman Gazi University School of Medicine , Eskişehir , Turkey.
Pınar
P
Dal
q Department of Medical Oncology , Kent Hospital , Mugla , Turkey.
İbrahim
İ
Petekkaya
a Department of Internal Medicine and Medical Oncology , Sakarya University School of Medicine , Sakarya , Turkey.
Ceyhun
C
Varım
a Department of Internal Medicine and Medical Oncology , Sakarya University School of Medicine , Sakarya , Turkey.
Hakan
H
Cinemre
D014408:Biomarkers, Tumor / Q000097:blood*; D002292:Carcinoma, Renal Cell / Q000097:blood* / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology; D005260:Female; D006454:Hemoglobins / Q000378:metabolism*; D006801:Humans; D007680:Kidney Neoplasms / Q000097:blood* / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D011237:Predictive Value of Tests; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D012189:Retrospective Studies
D014408:Biomarkers, Tumor; D006454:Hemoglobins; D047428:Protein Kinase Inhibitors; D011505:Protein-Tyrosine Kinases
Hemoglobin; predictive; renal cell carcinoma; survival; tyrosine kinase inhibitor